Actively Recruiting
Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction Following Oral Squamous Cell Carcinoma Resection and Drugs-induced Osteonecrosis
Led by AO Innovation Translation Center · Updated on 2025-09-04
300
Participants Needed
19
Research Sites
433 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Prospective will be collected in a minimum of 300 patients presenting with an acquired segmental mandibular defect ≥ 2 cm secondary to OSSC removal and drugs-induced osteonecrosis, and who require mandibular reconstruction.
CONDITIONS
Official Title
Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction Following Oral Squamous Cell Carcinoma Resection and Drugs-induced Osteonecrosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with pathological diagnosis of mandibular involvement by oral tumors, drug-induced osteonecrosis, or metastatic mandibular lesions
- Age 18 years and older
- Bisphosphonate related osteonecrosis of the mandible
- Immunomodulatory drugs induced mandibular osteonecrosis
- Patients with ameloblastoma affecting the mandible
- Patients with osteosarcomas of the mandible
- Patients with oral metastases related mandibular lesions indicated for segmental resection
- Undergoing primary curative treatment with segmental mandibular resection 2 cm or larger
- Plan to undergo mandibular reconstruction with autologous bone using primary or secondary approach
- Ability to understand and provide informed consent or have consent provided according to approved procedures
You will not qualify if you...
- Tumors affecting the condyle
- Patients under palliative care
- Previous extensive mandibular surgeries that may affect study outcomes
- Intraoperative exclusion: nonsegmental mandibular defect or defect less than 2 cm
- Mandibular defects extending beyond the sigmoid notch into the condyles
- No autologous bone reconstruction performed within 18 months after resection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 19 locations
1
University of Florida College of Medicine
Jacksonville, Florida, United States, 32209
Actively Recruiting
2
University of Illinois Chicago
Chicago, Illinois, United States, 60612
Actively Recruiting
3
Northwell Health Cancer Institute
New Hyde Park, New York, United States, 11042
Not Yet Recruiting
4
Mount Sinai Hospital
New York, New York, United States, 10029
Actively Recruiting
5
John Peter Smith Health Network
Fort Worth, Texas, United States, 76104
Actively Recruiting
6
Universitätsklinikum Tübingen
Tübingen, Baden-Wurttemberg, Germany, 72076
Actively Recruiting
7
University Hospital RWTH Aachen
Aachen, Germany, 52074
Actively Recruiting
8
University Hospital Charité
Berlin, Germany, 13353
Actively Recruiting
9
Hannover Medical School
Hanover, Germany, 30625
Actively Recruiting
10
Universitätsklinikum Heidelberg
Heidelberg, Germany, 69120
Actively Recruiting
11
University Hospital Leipzig
Leipzig, Germany, 04103
Actively Recruiting
12
Klinikum der LMU München
Munich, Germany, 80337
Actively Recruiting
13
University Hospital Ulm
Ulm, Germany, 89081
Actively Recruiting
14
Shimane University
Izumo, Japan, 693-0001
Not Yet Recruiting
15
Erasmus University Medical Centre
Rotterdam, Netherlands, 3015 GD
Actively Recruiting
16
Luz Hospital
Lisbon, Portugal, 1500-650
Not Yet Recruiting
17
12 de Octubre
Madrid, Spain, 28041
Actively Recruiting
18
Uppsala University Hospital
Uppsala, Sweden, 75185
Actively Recruiting
19
University Hospital Basel
Basel, Switzerland, 4031
Actively Recruiting
Research Team
M
Maria Medina Giner
CONTACT
M
Marco Minoia, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here